interferon also interferon beta cytokine interferon family used treat multiple sclerosis produced mammalian cells interferon produced modified e research indicates interferon injections may result reduction rate ms interferon beta shown slow advance interferons cure ms known cure claim interferons may slow progress disease started early continued duration earliest clinical presentation relapsingremitting multiple sclerosis clinically isolated syndrome cis single attack single symptom cis subacute attack suggestive demyelination included spectrum ms treatment interferons initial attack decreases risk developing clinical definite medications modestly effective decreasing number attacks relapsingremitting multiple reducing accumulation brain lesions measured using gadoliniumenhanced magnetic resonance imaging interferons reduce relapses approximately safe profile make firstline nevertheless patients responsive therapies known ms patients nonresponsive beta classified genetic pharmacological pathogenetic one factors related nonrespondance presence high levels interferon beta neutralizing antibodies interferon therapy specially interferon beta induces production neutralizing antibodies usually second months treatment treated moreover subset rrms patients specially active ms sometimes called rapidly worsening ms normally nonresponders interferon beta studies longterm effects drugs existing data effects interferons indicate earlyinitiated longterm therapy safe related better interferon available injectable forms cause skin reactions injection site may include cutaneous necrosis skin reactions interferon beta common subcutaneous administration vary greatly clinical usually appear within first month treatment albeit frequence importance diminish six months skin reactions prevalent mild skin reactions usually impede treatment whereas necroses appear around patients lead discontinuation also time visible dent injection site due local destruction fat tissue known lipoatrophy may develop however rarely occurs interferon interferons subclass cytokines produced body illnesses influenza order help fight infection responsible many symptoms influenza infections including fever muscle aches fatigue many patients report influenzalike symptoms hours taking interferon beta usually improve within hours symptoms related temporary increase reaction tends disappear months treatment symptoms treated overthecounter nonsteroidal antiinflammatory drugs ibuprofen reduce fever another common transient secondary effect interferonbeta functional deterioration already existing symptoms deterioration similar one produced ms patients due heat fever stress uhthoffs phenomenon usually appears within hours treatment common initial months treatment may last several symptom specially sensitive worsening interferonbeta also reduce numbers white blood cells leukopenia lymphocytes lymphopenia neutrophils neutropenia well affect liver cases effects nondangerous reversible cessation reduction nevertheless recommendation patients monitored laboratory blood analyses including liver function tests ensure safe use help prevent injectionsite reactions patients advised rotate injection sites use aseptic injection technique injection devices available optimize injection process side effects often onerous enough many patients ultimately discontinue taking interferonscitation needed glatiramer acetate comparable diseasemodifying therapy requiring regular injections interferon beta balances expression pro antiinflammatory agents brain reduces number inflammatory cells cross blood brain overall therapy interferon beta leads reduction neuron moreover also thought increase production nerve growth factor consequently improve neuronal vitro interferon beta reduces production cells subset lymphocytes believed role pathophysiology avonex approved us european union registered countries worldwidecitation needed leading ms therapy us around overall market european union around overall marketcitation needed produced biogen biotechnology company originally competition protection us orphan drug act avonex sold three formulations lyophilized powder requiring reconstitution premixed liquid syringe kit pen administered via intramuscular rebif diseasemodifying drug dmd used treat multiple sclerosis cases clinically isolated syndromes well relapsing forms multiple sclerosis similar interferon beta protein produced human body comarketed merck serono pfizer us exception orphan drug actcitation needed approved european union us since approved countries worldwide including canada australiacitation needed emd serono sole rights rebif us since january rebif administered via subcutaneous cinnovex brand name recombinant interferon manufactured biosimilarbiogeneric iran produced lyophilized form sold distilled water injection cinnovex developed fraunhofer society collaboration cinnagen first therapeutic protein fraunhofer laboratory approved biogeneric biosimilar medicine several clinical studies prove similarity cinnovex watersoluble variant currently investigated vakzine projekt management vpm gmbh braunschweig germany plegridy brand name pegylated form interferon plegridys advantage needs injecting every two closely related interferon interferon also indicated ms formulated different dose administered different frequency drug different safetyefficacy interferon marketed bayer us betaseron outside us betaferon united states cost per mcg national average drug acquisition cost nadac united states avonex mcg avonex rebif top ten bestselling multiple sclerosis drugs example specialty drug would available specialty pharmacy requires refrigerated chain distribution costs interferon administered subcutaneously intravenously investigated since march potential treatment patients hospitalized multinational solidarity trial initially combination lopinavir reduce inhospital mortality compared local standard inhalation formulation interferon developed treatment pilot trial hospitalized patients showed higher odds clinical improvement compared january phase trial population